Novavax | NVAX - Gastos De Venta Y Administración





Gastos De Venta Y Administración Cambio Fecha
Adma Biologics USD 20.19M 2.86M 2025-12
Agenus USD 10.56M 13.04M 2025-12
AstraZeneca USD 5.06B 455M 2026-03
BioCryst Pharmaceuticals USD 95.78M 12.77M 2025-12
Cassava Sciences USD 6.66M 1.24M 2025-12
Geron USD 35.42M 6.24M 2026-03
GlaxoSmithKline GBP 2.12B 558M 2026-03
MannKind USD 54.08M 4.33M 2026-03
Merck USD 2.67B 180M 2026-03
Minerva Neurosciences USD 2.48M 58.79K 2024-09
Moderna USD 173M 135M 2026-03
Novartis USD 3.44B 132M 2025-12
Novavax USD 25.53M 1.34M 2025-12
Pfizer USD 2.92B 1.16B 2026-03
Sanofi EUR 2.33B 419M 2026-03
Sarepta Therapeutics USD 54.03M 51.35M 2026-03
TG Therapeutics USD 73.14M 22.42M 2026-03